Skip to main content
Unchecking box will stop auto data updates
Cboe BZX Real-Time Last Sale USD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 20.73
Day High 21.52
Open:20.90
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Description
Exelixis, Inc. is a biopharmaceutical company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its development and commercialization efforts primarily on COMETRIQ' (cabozantinib), its wholly-owned inhibitor of multiple receptor tyrosine kinases. Another Exelixis-discovered compound, cobimetinib, a selective inhibitor of MEK, is being evaluated by Roche and Genentech (a member of the Roche Group) in a broad development program under a collaboration with Exelixis.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Report: Developing Opportunities within Exelixis, Cintas, BGC Partners, FirstEnergy, Hologic, and Trevena -- Future Expectations, Projections Moving into 2018
GlobeNewswire - Wed Dec 12, 6:30AM CST
GlobeNewswire - CMTX
Wed Dec 12, 6:30AM CST
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Exelixis, Inc. (NASDAQ:EXEL), Cintas Corporation (NASDAQ:CTAS), BGC Partners, Inc. (NASDAQ:BGCP), FirstEnergy Corporation (NYSE:FE), Hologic, Inc. (NASDAQ:HOLX), and Trevena, Inc. (NASDAQ:TRVN), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Exelixis and Ipsen Initiate Phase 3 Pivotal Trial (COSMIC-312) of Cabozantinib in Combination with Atezolizumab versus Sorafenib in Previously Untreated Advanced Hepatocellular Carcinoma
BusinessWire - Wed Dec 5, 12:30AM CST
BusinessWire - CMTX
Wed Dec 5, 12:30AM CST
Exelixis, Inc. (Nasdaq:EXEL) and Ipsen (Euronext:IPN; ADR:IPSEY)today announced the initiation of COSMIC-312, a phase 3 pivotal trial of cabozantinib (CABOMETYX(R)) in combination with atezolizumab (TECENTRIQ(R)) versus sorafenib in previously untreated advanced hepatocellular carcinoma (HCC). The co-primary endpoints of the trial are progression-free survival and overall survival. An exploratory arm will also evaluate cabozantinib monotherapy in this first-line setting.
Biotech's Tackling Major Issues You Should Know
ACCESSWIRE - Thu Nov 29, 11:07AM CST
ACCESSWIRE - CMTX
Thu Nov 29, 11:07AM CST
HENDERSON, NV / ACCESSWIRE / November 29, 2018 / Here are a few biotech/ healthcare and CBD companies that require your attention.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 16.86 +24.73% increase
on 11/15/18
Period Open:16.76
Price movement based on the high, low and last over the given period.
22.37 -5.99% decrease
on 12/12/18
+4.27 (+25.48%) increase
since 11/14/18
3-Month 13.42 +56.71% increase
on 10/29/18
Period Open:16.97
Price movement based on the high, low and last over the given period.
22.37 -5.99% decrease
on 12/12/18
+4.06 (+23.92%) increase
since 09/14/18
52-Week 13.42 +56.71% increase
on 10/29/18
Period Open:25.95
Price movement based on the high, low and last over the given period.
32.20 -34.69% decrease
on 01/04/18
-4.92 (-18.96%) decrease
since 12/14/17

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2018.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

More stories below advertisement